Neopharm, led by CEO Kim Yang-soo, announced on the 13th that it successfully concluded the 'WAVE: UNFOLDED GRAND SYMPOSIUM' in collaboration with Hire Corporation, headed by CEO Kim In-yong. Held on June 27 at the Grand Walkerhill Seoul, this event was a landmark gathering aimed at sharing the clinical direction of HILO WAVE® and exploring developmental trajectories in the aesthetic medical field.

Attracting over 300 attendees, including medical professionals from dermatology and plastic surgery, this symposium marked the largest event in the company’s history. The agenda kicked off with a keynote address from CEO Kim Yang-soo, followed by three comprehensive sessions focused on the biological mechanisms of the HILO WAVE DHC® ingredient and various clinical application cases.

The first two sessions presented detailed scientific insights, while the third engaged in a panel discussion that synthesized clinical experiences, product introduction criteria, and management know-how. The event featured seven speakers and eight panelists, emphasizing a collaborative approach to knowledge dissemination in the medical community.

Neopharm secured the domestic distribution rights for HILO WAVE in April of last year. Currently, they are the exclusive supplier to domestic medical institutions, an arrangement that positions them favorably in an emerging market for advanced aesthetic solutions.

A company representative stated, 'This symposium was a significant opportunity for domestic medical professionals to share the latest clinical experiences and foster diverse discussions.' This reinforces Neopharm’s commitment to leveraging professional channel competitiveness to deliver differentiated solutions in the aesthetic segment.

The HILO WAVE, developed by Hire Corporation, is a dual-hyaluronic acid-based collagen booster. It features a hybrid composite formulation that includes both high-molecular and low-molecular hyaluronic acid. Having passed the review of the Ministry of Food and Drug Safety, it has received certification as a Class IV medical device intended for tissue restoration.